|
POLD3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.22909999999521E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.058910E-03 |
| Normal-vs-Stage2 |
9.62409999999414E-05 |
| Normal-vs-Stage3 |
1.74976999999243E-05 |
| Normal-vs-Stage4 |
3.32589999996191E-06 |
| Stage1-vs-Stage2 |
8.660100E-02 |
| Stage1-vs-Stage3 |
6.231900E-02 |
| Stage1-vs-Stage4 |
2.030300E-02 |
| Stage2-vs-Stage3 |
7.446000E-01 |
| Stage2-vs-Stage4 |
8.558000E-01 |
| Stage3-vs-Stage4 |
5.740600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44659999999653E-05 |
| Normal-vs-AfricanAmerican |
4.195500E-02 |
| Normal-vs-Asian |
2.180200E-02 |
| Caucasian-vs-AfricanAmerican |
5.420400E-01 |
| Caucasian-vs-Asian |
2.441400E-01 |
| AfricanAmerican-vs-Asian |
8.157200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.27780000000766E-06 |
| Normal-vs-Female |
1.191310E-04 |
| Male-vs-Female |
1.879790E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.580100E-03 |
| Normal-vs-Age(41-60Yrs) |
1.405680E-04 |
| Normal-vs-Age(61-80Yrs) |
2.30589999983266E-07 |
| Normal-vs-Age(81-100Yrs) |
9.219800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.933040E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.097500E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.282600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.638200E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.597400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.980600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.336000E-02 |
| Classical-VS-Follicular |
1.004600E-04 |
| Classical-VS-Other |
1.181160E-01 |
| Classical-VS-Normal |
2.615500E-03 |
| Tall-VS-Follicular |
4.668000E-01 |
| Tall-VS-Other |
6.245400E-01 |
| Tall-VS-Normal |
3.788500E-04 |
| Follicular-VS-Other |
9.556200E-01 |
| Follicular-VS-Normal |
5.0277999996684E-07 |
| Other-VS-Normal |
1.456060E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.93099999995705E-06 |
| Normal-vs-N1 |
1.72576999999396E-05 |
| N0-vs-N1 |
5.349200E-01 |
|
|
